In the basement of RCSI University in Dublin, researchers have engineered something the human heart has been doing flawlessly for millennia—a synthetic mitral valve that actually behaves like the real thing. Dr. Claire Conway and her team have created the first artificial valve model that captures not just the structure, but the complex mechanical personality of the valve that opens and closes roughly 100,000 times every single day in a healthy human heart.
This breakthrough matters because when the mitral valve fails, the consequences ripple through millions of lives. The condition known as mitral regurgitation—where blood leaks backward through the heart—affects tens of millions of people globally. As populations age and life expectancy climbs, cardiologists expect this number to grow significantly, making better treatments not just a medical goal but an urgent public health priority.
For decades, synthetic mitral valves have fallen short in a crucial way: they lacked anisotropy, the property of having different mechanical behaviors depending on the direction of force applied to them. Real heart valve tissue isn't uniform—it responds differently to pressure from different angles, just as wood is stronger along its grain than across it. Previous models couldn't replicate this property, and they couldn't withstand the intense pressures and blood flow rates that occur naturally inside the beating heart. They were, essentially, approximations that broke under real-world conditions.
The RCSI model changes that equation entirely. Published in Acta Biomaterialia, this synthetic valve is the first to successfully incorporate the mechanical properties of actual heart valve tissue while functioning under realistic physiological pressures and flow conditions. When the team put it through both physical and digital testing, it performed as a native valve would—a result that Dr. Conway describes as "a significant advance in the field."
What makes this innovation particularly powerful is the precision it offers. Researchers can now adjust the tension and thickness of the valve leaflets—the tissue flaps that perform the opening and closing action—with exact control, while the valve still replicates how it functions in the living heart. Dr. Sina Javadpour, the study's first author and a postdoctoral fellow at Trinity College Dublin, emphasizes that this combination is what transforms a laboratory model into a research tool. "That makes it a powerful tool for studying valve disease and testing new repair strategies in a controlled laboratory environment," he explains.
The implications extend far beyond a single research institution. Because many mitral valve problems stem from alterations in the tissue's mechanical properties, having a model that behaves like human tissue offers researchers a window into how these conditions begin and progress. Scientists worldwide can now test new repair approaches and understand valve dysfunction in ways previously impossible. And because the model is low-cost and the fabrication is precise and repeatable, it could eventually become accessible to heart research teams globally.
For patients living with mitral valve disease today, this synthetic model represents something hopeful: a foundation for developing the treatments and interventions that could prevent or reverse the condition that affects their hearts with every single beat.